Backgrounds/Aims: Hepatocellular adenoma (HCA) is a rare benign tumor that has a risk of malignant transformation into hepatocellular carcinoma (HCC) and bleeding. The aim of this study was to analyze the characteristics of HCA by performing molecular classification. Methods: We retrospectively collected data from nine patients who were diagnosed with HCA from 1995 to 2016. The patients underwent liver surgery due to the existence of clinical symptoms. Immunohistochemical (IHC) staining was performed to classify the subgroups of HCA. Results: Four patients with both -catenin and inflammation were classified as -IHCA. Two patients were defined as -HCA. Two patients were classified as HHCA. Only one patient was defined as IHCA. None of the patients had unclassified HCA. Seven of nine patients had a malignant transformation. By comparing the characteristics of HCA between two groups, we found the mean tumor size in the malignant transformation group was greater than the non-malignant transformation group. Conclusions: Taken together, the mean tumor size and activation of catenin 1 mutation status might be the risk factors for the malignant transformation of HCA into HCC. Moreover, IHCA without the catenin 1 mutation could also have a possibility of malignant transformation into HCC. 
INTRODUCTION
Hepatocellular adenoma (HCA) is a rare benign tumor that occurs frequently in women of reproductive age with a history of oral contraceptives (OCs) use. 1 As a result of cultural differences, OCs are more commonly used in Western countries, leading to a higher incidence of HCA compared with that in Eastern countries. [2] [3] [4] However, exposure to androgens or underlying metabolic syndrome including glycogen storage disease (GSD) type 1a and
Fanconi anemia, which can also affect men, promotes HCA occurrence. [5] [6] [7] Although benign, HCA can be complicated by rupture and hemorrhage and require surgical intervention. 8 Hepatocellular carcinoma (HCC) may arise from HCA, which is known as malignant transformation.
Malignant transformation is a rare event, with a reported incidence of 4.7-10.6% in patients with HCA. [9] [10] [11] [12] Recent classification divides HCA into five categories:
HHCA, -HCA, IHCA, ShHCA and unclassified HCA.
HCA with inactivate biallelic mutations of hepatocyte nuclear factor 1 (HNF1A) are defined as HHCA. [13] [14] [15] HCA with mutations of -catenin (CTNNB1) are referred to as -HCA. Inflammatory HCA results from mutations that activate the IL-6/JAK/STAT pathway. 16 
MATERIALS AND METHODS

Patient characteristics
We collected data from nine patients diagnosed with
HCA by pathological examination in our department. In order to find out the correlation with malignant transformation, the patients were divided into malignant transformation and non-malignant transformation groups.
Results of preoperative clinical test, follow-up data and history of exposure to exogenous steroids were recorded.
Statistical analysis
For continuous variables, data were synopsized as mean 
RESULTS
Clinical data
The characteristics of nine patients are summarized in Pathological data IHC staining was performed using antibodies with -catenin, SAA, CRP, GS, LFABP and to classify the categories of HCA (Fig. 1) . All nine patients were negative for -catenin antibody staining. Further, to exam the cat- 
enin 1 mutation, we used GS staining for the diagnosis.
Results of staining are displayed in Table 3 . three patients (4.4%) had a tumor size ＜5 cm. 20 In our series, although there is no statistical basis due to the small number of cases, we found that the mean tumor size was 11.2cm in the malignant transformation group, greater than non-malignant transformation group.
Metabolic syndrome was considered to be a new risk factor for malignant transformation. Underlying GSD is a known strong risk factor for development of HCA; however, malignant transformation was not observed during follow-up. 23 There are a few reports of malignant transformation of HCA into HCC in patients with GSD. [24] [25] [26] In a study of 25 HCAs from 15 patients with GSD, HCAs were classified as -HCA, IHCA and unclassified HCA by IHC staining, and no HNF1A inactivation was found. 27 In the present study, one patient with underlying GSD developed malignant transformation, and the HCA was classified as IHCA by IHC staining.
Catenin 1 mutation is considered to be one of the main risk factors for malignant transformation of HCA into HCC. 28 Because of the low sensitivity of -catenin staining in detecting mutation of catenin 1, GS staining was used to assist the diagnosis. Among seven patients in the malignant transformation group, six were associated with mutation of -catenin, including four with -IHCA and two with -HCA. Surprisingly, in respect of detecting catenin 1 mutation, all six HCAs were negative for -catenin staining but positive for GS staining. We consider that GS staining appeared to be more sensitive than -catenin staining in detecting catenin 1 mutation. Malignant transformation has not been found in the subgroup of IHCA that is negative for catenin 1 mutation.
However, we found that the patient E in Table 3 was classified as IHCA with absence of catenin 1 mutation (negative for -catenin and GS IHC staining), that had a malignant transformation. We consider that there is an unknown pathway regulating malignant transformation in IHCA.
Our study revealed that the mean tumor size and activation of catenin 1 mutation status might be the risk factors for the malignant transformation of HCA into HCC.
Interestingly, a single patient with underlying GSD was classified as IHCA, that had a malignant transformation to HCC. Our results support further studies of the correlation between IHCA and HCC.
